Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of magnetic resonance imaging (MRI) diagnosis of perianal fistula associated with Crohn's disease

Brief summary (registry, in English)

To validate the use of 0.05 mmol/kg of Gadopiclenol in the detection and monitoring of perianal fistulas by magnetic resonance imaging studies.

What you commit to

• Study type: Interventional · Phase 4
• Planned participants: 30
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Crohn's disease who also have a perianal fistula (a tunnel near the anus) caused by it. It compares two MRI contrast agents.

Age

18 years or older

Sex

All sexes can join

Disease stage

Crohn's disease with perianal disease caused by it

Main reasons for not taking part

• Younger than 18 years
• Pregnant or breastfeeding
• Kidney failure (GFR below 30 ml/min in lab results up to 6 months old)
• Past allergic reaction to gadolinium contrast media
• Crohn's disease without perianal disease

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details